Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update
12 nov. 2024 16h05 HE
|
Longeveron
Longeveron reports 3Q24 financial results. Pivotal Phase 2b clinical trial in HLHS achieves 80% enrollment. Positive Phase 2 data for Alzheimer's disease.
Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)
11 nov. 2024 09h05 HE
|
Longeveron
Longeveron has appointed Devin Blass as Chief Technology Officer (CTO) and SVP of CMC, effective Dec 2, adding capabilities ahead of potential BLA filing.
Stem Cell Therapy Market Analysis Report 2024-2029: iPSC Technology and Personalized Medicine Trends Drive Growth
06 nov. 2024 05h12 HE
|
Research and Markets
Dublin, Nov. 06, 2024 (GLOBE NEWSWIRE) -- The "Stem Cell Therapy Market: Analysis By Type, By Stem Cell Source, By Application, By End User, By Region Size and Trends Forecast up to 2029" report has...
Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
04 nov. 2024 16h05 HE
|
Longeveron
Longveron will report third quarter 2024 financial results and provide a business update on Tuesday, November 12th after the U.S. financial markets close.
Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)
29 oct. 2024 10h00 HE
|
Longeveron
Longeveron presents clinical data for stem cell therapy in Alzheimer's disease. Findings offer potential mechanistic and clinical insights.
RMS Sponsors the 5th Summit on Stem Cell Derived Islets
29 oct. 2024 09h00 HE
|
Regenerative Medical Solutions
Boston, MA, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Regenerative Medical Solutions (RMS) is sponsoring the 5th Summit on Stem Cell Derived Islets, which will be held on October 28-29 at the Joseph B....
Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting
27 oct. 2024 15h10 HE
|
Longeveron
Longeveron reports positive long-term transplant-free survival (100% survival) data from a multi-year study in Hypoplastic Left Heart Syndrome (HLHS)
Amyotrophic Lateral Sclerosis Treatment Market to hit USD 1.1 billion by 2032, says Global Market Insights Inc.
24 oct. 2024 05h30 HE
|
Global Market Insights Inc.
Selbyville, Delaware, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Amyotrophic Lateral Sclerosis (ALS) Treatment Market size was valued at USD 713.3 million in 2023 and is expected to grow at a CAGR of 5.5%...
Longeveron® Lomecel-B™ Data in Alzheimer’s Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)
14 oct. 2024 09h05 HE
|
Longeveron
Longeveron Lomecel-B data in Alzheimer's disease selected for late breaking poster presentation at Clinical Trials on Alzheimer’s Disease Conf (CTAD24).
Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day
07 oct. 2024 09h05 HE
|
Longeveron
Wa’el Hashad, Chief Executive Officer of Longeveron, will participate in a Fireside Chat at the UBS Virtual Organ Restoration and Cell Therapy Day Oct 15th